MLAB Stock Recent News
MLAB LATEST HEADLINES
Mesa Labs (MLAB) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.22 per share a year ago.
In Q3, Mesa Laboratories reported mixed results throughout the P&L with soft bottom-line fundamentals. FCF growth still lumpy with contraction in divisional growth.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
After Q2 results, EPS estimates soar 39% as revenues grow 24% on strong M&A strategies
LAKEWOOD, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2023 at approximately 8:00 A.M. Eastern time on Monday, February 6, 2023.
Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.